Corporate Symposia

Corporate Symposia

Corporate Lunch Symposium 1: Eisai

Brain tumour related epilepsy: what is the evidence for targeting the AMPA glutamate receptor?

This promotional symposium has been organised and funded by Eisai Europe Ltd.  This meeting is intended for HCPs. The content is aligned with EU and UK marketing authorisations and approved according to ABPI and EFPIA codes.

EMEA-PER-21-00081 | August 2021

Saturday, September 25, 12:30 - 13:30 hrs

Chair: Dr Gilles Huberfeld (Paris, FR)

12:30 – 12:35Welcome and Introductions

Dr Gilles Huberfeld, Neurologist,

Hospital Foundation Adolphe De Rothschild, France

12:35 – 12:50

Pathogenesis of brain tumour related epilepsy (BTRE): what is the role of the glutamatergic system?

Dr Gilles Huberfeld, Neurologist,

Hospital Foundation Adolphe De Rothschild, France

12:50 – 13:05Targeting the AMPA glutamate receptor for BTRE

Dr Antonietta Coppola, Assistant Professor of Neurology,

University of Naples Federico II, Italy

13:05 – 13:20Quality of life in patients with BTRE: looking beyond seizure control

Dr Katherine Peters, Associate Professor of Neurology and Neurosurgery,

Preston Robert Tisch Brain Tumor Center, Duke University, USA

13:20 – 13:30Q&A/Discussion



Seizures are among the most common symptoms of brain tumours and can have a substantial impact on the daily lives of patients. The mechanism of epileptogenesis is not completely understood but is believed to be multifactorial, with evidence identifying glutamate as one of the key drivers for brain tumour related epilepsy (BTRE). Proposed mechanisms of seizure generation in patients with BTRE will be outlined; and data for this patient population from a prospective,multicentre observational study using an antiseizure medication (ASM), which targets the glutamate AMPA receptor, will be presented. Furthermore, the quality of life in BTRE patients will be discussed and how an individualised approach is required for choosing an ASM to help maintain good seizure control without increasing the overall burden to patients and their families.

Corporate Lunch Symposium 2: AstraZeneca

Evolving landscape in the treatment of plexiform neurofibromas associated with NF1

This promotional satellite symposium is intended for healthcare professionals and is organised and funded by AstraZeneca​ Veeva ID: Z4-36912        

Date of Preparation: September 2021

Saturday, September 25, 12:30 - 13:30 hrs

Chair: Amedeo Azizi, (Austria)

12:30 – 12:40Unmet clinical need and burden of disease in NF1

Amedeo Azizi, Austria

12:40 – 13:00

The treatment landscape of NF1-PNs

Darren Hargraves, United Kingdom 

13:00 – 13:20NF1-PN clinical cases

João Passos, Portugal

13:20 – 13:30Live Audience Q&A


Plexiform neurofibromas (PNs) present in 30-50% of patients with neurofibromatosis type 1 (NF1). PNs typically manifest early, developing rapidly in early childhood and have the potential to cause significant pain, disability, and disfigurement, depending on their location and size.

Historically, the only treatment for PNs was surgery, but some are difficult to fully resect due to tissue infiltration and hypervascularisation. MEK inhibitors, such as selumetinib, have been investigated as a therapeutic option for the treatment of inoperable NF1-PNs.

This symposium will discuss the current treatment landscape for NF1-PNs, including data from the Phase II SPRINT clinical trial, evaluating selumetinib for the treatment of symptomatic, inoperable NF1-PN in children and adolescents, and case studies from early access programs, showing use of selumetinib in clinical practice.

Link to Koselugo (selumetinib) EU prescribing information: